Regulation of transthyretin to treat obesity
AssigneeBayer Aktiengesellschaft
InventorLinda H. Wu
Life of this patent
Estimating the term…
Abstract
Reagents that regulate transthyretin and reagents which bind to transthyretin gene products can play a role in preventing, ameliorating, or correcting obesity and related dysfunctions.
Claims40
A method of identifying potential anti-obesity agents, comprising the steps of:
- contacting a transthyretin with a test compound;
- and
- identifying the test compound as a potential anti-obesity agent if it binds to the transthyretin.
A method of identifying potential anti-obesity agents, comprising the steps of:
- contacting a polynucleotide encoding a transthyretin with a test compound under conditions which permit expression of the transthyretin;
- and
- identifying the test compound as a potential anti-obesity agent if it reduces expression of the transthyretin relative to expression of the transthyretin in the absence of the test compound.
A method of identifying potential anti-obesity agents, comprising the steps of:
- contacting a transthyretin and a thyroxine with a test compound under conditions which permit binding of the transthyretin and the thyroxine;
- and
- identifying the test compound as a potential anti-obesity agent if it reduces binding of the transthyretin and the thyroxine relative to binding of the transthyretin and the thyroxine in the absence of the test compound.
A pharmaceutical composition for treating obesity, comprising:
- a reagent that specifically binds to transthyretin;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition for treating obesity, comprising:
- an antibody that specifically binds to transthyretin;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition for treating obesity, comprising:
- an antisense oligonucleotide that hybridizes to a polynucleotide encoding transthyretin and reduces expression of the polynucleotide;
- and
- a pharmaceutically acceptable carrier.
A method of treating obesity, comprising the step of:
- administering to a patient in need thereof an effective amount of a reagent that decreases binding of transthyretin to thyroxine, whereby symptoms of the patient's obesity are decreased.
A method of treating obesity, comprising the step of:
- administering to a patient in need thereof an effective amount of an antibody that specifically binds to transthyretin and decreases binding of transthyretin to thyroxine, whereby symptoms of the patient's obesity are decreased.
A method of treating obesity, comprising the step of:
- administering to a patient in need thereof an effective amount of an oligonucleotide that hybridizes to a polynucleotide encoding transthyretin and reduces expression of the polynucleotide, whereby symptoms of the patient's obesity are decreased.
Dependencies are inferred from the claim text.